The binding of biologically active and 1251-labeled neurotrophin-3 (NT-3) was studied with both dry film and emulsion autoradiography to compare with NGF binding and discover areas where NT-3 may function in vivo. The equilibrium binding of 300 PM 1251-NT-3 to rat brain sections was reversible and inhibited by unlabeled , , 420 PM) . 1251-NT-3 bound in a saturable manner, with high affinity (K, , , and with a capacity (B,,,, 26 fmol/mg protein) that exceeded that of NGF by threefold.
As with NGF, '261-NT-3 also bound to a second population of sites with lower affinity (K,, 2.6 nM) and higher capacity (B,,,, 170 fmol/mg protein). 1251-NT-3 binding was not blocked by NGF, or serum proteins, and brain-derived neurotrophic factor (BDNF) competed for it in a distinctly biphasic manner (IC,, values of 230 PM and 37 nM). Microdensitometry confirmed graphically and by Hill analysis the monophasic displacement of '251-NT-3 and the biphasic displacement of Y-NT-3 binding by BDNF in hippocampus, caudate-putamen, neocortex, and olfactory tubercle. In rat or cat, the topography of Y-NT-3 binding differed from that reported for Y-NGF binding or for the lowaffinity NGF receptor.
The highest binding densities were found in neocortical layers 1 and 2, the stratum oriens and radiatum of hippocampus, molecular layer of the dentate gyrus, nucleus of the lateral olfactory tract, entorhinal cortex, anterior olfactory nucleus, anteromedial thalamic nucleus, and amygdala. Moderate densities were found in neocortical layers 4-6, the neostriatum, amygdala, the dorsal root ganglia, and the central gray of spinal cord. Emulsion autoradiography also revealed binding in nerve terminal-rich regions of superficial neocortex and hippocampus but not on neural cell bodies. Binding was absent in many other brain regions, including cholinergic nuclei, and in all peripheral organs studied including liver, kidney, pancreas, heart, and skeletal muscle. *WNT-3 binding to sections of human basal ganglia resembled that seen in rat or cat, including high densities in the caudate, putamen, and superficial neocortex. The unique distribution and pharmacology of Y-NT-3 binding to BDNF-sensitive and -insensitive sites in brain predict predominantly neuronal actions for these factors that Received July 8, 1992; accepted Aug. 21, 1992 . We greatly appreciate the excellent technical assistance of Dr. Ann Acheson and Michelle Russell in conducting bioassays of NT-3, BDNF, NGF, and 1211-NT-3 with dissociated DRG neurons, the statistical analysis of Nancy Stambler, the preparation of the illustrations by Beverly Irish and Nannette Butler, and manuscript typing by Janet Clark. Discussions with Dr. Jesse Cedarbaum concerning potential therapeutic applications of NT-3 based on the receptor topography data are also greatly appreciated.
Correspondence should be addressed to C. Neurotrophin-3 (NT-3) is a member of the NGF family of molecules termed neurotrophins that support the survival and outgrowth of brain and peripheral neurons (Hohn et al., 1990; Maisonpierre et al., 1990a,b; Rosenthal et al., 1990; see Thoenen, 199 1, for review). The localization of NT-3 mRNA by Northern analysis and in situ hybridization reveals a widespread distribution in both brain and periphery, with high levels not only in cerebellum, hippocampus, neocortex, and midbrain but also in kidney, heart, spleen, skin, gut, lung, liver, and muscle (Enfors et al., 1990; Hohn et al., 1990; Maisonpierre et al., 1990a,b) . Predictions of the brain regions or peripheral targets upon which NT-3 is likely to act in vivo or in vitro would be facilitated by the use of NT-3 binding assays. However, NT-3 binding has been studied only with cultured fibroblasts (Lamballe et al., 1991; Soppet et al., 1991; Squint0 et al., 1991) and in homogenates of hippocampus from 2-week-old rats (Soppet et al., 199 1) . In contrast, many studies over the last decade have characterized lZ51-NGF binding to a variety of tissues, including analysis by receptor autoradiography (Richardson et al., 1986; Raivich and Kreutzberg, 1987; Altar et al., 1991a,b) . These autoradiographic studies show that 1251-NGF binding is found mostly in the brain, spinal cord, and dorsal root ganglia (DRG). Within brain, almost all 1251-NGF binding is found in a subset of forebrain cholinergic neurons of the medial septum, diagonal band, substantia innominata, hippocampus, and neostriatum. Of these areas, all but the neostriatum and hippocampus are labeled by monoclonal antibody 192 (Chandler et al., 1984) , which recognizes the low-affinity neurotrophin receptor (LNGFR; e.g., Cuello, 1988, 1990; Batchelor et al., 1989; Gibbs et al., 1989; Woolfet al., 1989) . Interestingly, many areas that are immunopositive for LNGFR contain little, if any, high-affinity binding of NGF (Yan and Johnson, 1989; Koh et al., 1989; Pioro and Cuello, 1990) . Other brain areas, such as thalamus, hypothalamus, and neocortex, are nearly devoid of both LNGFR immunostaining and high-affinity NGF binding. These observations raise the issue as to whether another neurotrophin family member, such as NT-3 or brain-derived neurotrophic factor (BDNF), may bind to these or other brain areas, and whether binding will predominate on cell bodies, as with lZ51-NGF, or in nerve terminal regions. Through the use of biologically active 1251- NT-3 (DiStefano et al., 1992) and receptor autoradiography, this article identifies high-affinity 1251-NT-3 binding in rat, cat, and human brain. Our results demonstrate that the distribution of l*SI-NT-3 binding to brain is distinct, more dense, and more widely distributed than that of 1251-NGF binding to brain. Under high-affinity binding conditions, lz51-NT-3 binds to BDNF-sensitive and -insensitive sites, demonstrating likely CNS roles for both neurotrophins in areas that do not contain high-or low-affinity NGF receptors.
Materials and Methods
Production and pur$cation of NT-3. Recombinant human NT-3 (119 amino acid residues) was produced in Chinese hamster ovary cells as previously described . The purity ofthe preparation was >95%; 50% was comprised of intact protein, and 50%, of cleaved product in which the first five N-terminal amino acids were missing. The NT-3 was monitored for biological activity using dissociated lumbar dorsal root ganglia (DRG) cells from embryonic day 8 (E8) chicken embryos maintained 2 d in vitro (Lindsay and Peters, 1984) . Murine NGF (muNGF, generously provided by Dr. Ralph Alderson, Regeneron Pharmaceuticals), BDNF, and NT-3 each mediated maximal survival of 50%, 30%, and 35%, respectively, of these DRG neurons, each with EC,, values of approximately 0.0 1 r&ml.
Iodination ofNT-3. NT-3 was iodinated by the lactoperoxidase method (Marchalonis, 1969) with several modifications ) that resulted in a specific activity of 2800-4400 cpm/fmol of NT-3 (14 14-2222 Ci/mmol of NT-3). jZ51-NT-3 was stored at SO-100 nM at 2-8°C and used within l-5 d after preparation. The biological activity of 1251-NT-3 was assessed by monitoring its ability to stimulate survival and neurite outarowth of dissociated E8 chicken DRG neurons, and this activity was c:mpared to unlabeled NT-3. lZSI-NT-3 was as potent as unlabeled NT-3 in the DRG bioassay over the entire O.OOl-1 @ml standard concentration range (not shown). lz51-NT-3 was also retronradelv transnorted from crushed sciatic nerve to the rat DRG, and shis transport was specifically blocked by unlabeled NT-3 (DiStefano et al., 1992) . The retrograde transport, the indistinguishable potencies of NT-3 and 1251-NT-3 in the DRG bioassay, and the inhibition of 1251-NT-3 binding by equal concentrations of NT-3 (see Results) indicate that the radioiodinated NT-3 used here was biologically equivalent to NT-3.
Tissues. Male Sprague-Dawley rats (200-250 gm; Zivic-Miller) were maintained on a 12: 12 hr light : dark cycle and given food and water ad libitum. The brain of each rat was frozen in isopentane at -15°C within 5 min of death. Serial 12-pm-thick coronal and horizontal sections of these tissues were collected at 0.30-0.50 mm intervals from the frontal cortex to the medulla at the level of the dorsal motor nucleus of the vagus (coronal sections) or through the olfactory bulbs, caudateputamen, and cerebellum (horizontal sections) and were used for association, dissociation, and equilibrium binding analyses. Sections were thaw-mounted onto 1% gelatin-coated 1 x 3 inch glass microscope slides and stored frozen for up to 1 month at -70°C. The brain of an adult male cat (provided by Dr. Max Cynader, University of British Columbia) was obtained within 0.5 hr post-mortem and frozen in isopentane as described for the rat brain. Coronal sections were prepared through the midbrain as described for the rat. Two male and two female human brains (generously provided by Drs. Satya Kar and Remi Quirion, Douglas Research Hospital, McGill University) were obtained 18-48 hr following death. Two patients aged 6 1 and 67 years died from myocardial infarction or ventricular fibrillation. Two patients aged 87 and 8 1 years had been diagnosed with Alzheimer's dementia and died following a brief coma or from complications of pneumonia. Coronal blocks of tissue through the basal ganglia including the caudate, putamen, and globus pallidus were dissected from each brain and frozen in isopentane as described for the rat. Twelve micron thick sections were obtained from the blocks and thaw-mounted onto 2 x 3 inch gelatin-coated microscope slides.
'251-NT-3 binding assay. Binding assays using brain sections were based on the '251-muNGF binding procedure of Richardson et al. (1986) with modifications (Altar et al., 199 la) . After thawing, each section was preincubated for 1 hr at 22°C in 100 mM phosphate-buffered saline (pH 7.4) containing 0.5 mM MgCl, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Prior studies showed equivalent binding for sections that were preincubated in buffer for 1, 3, or 24 hr (data not shown). Sections were then incubated in Dulbecco's modified Eagle's medium tissue culture medium containing high glucose, 10% heat-inactivated fetal calf serum (60°C for 0.5 hr), 25 mM HEPES buffer, 4 &ml leupeptin, 0.5 mM PMSF (Bethesda Research Labs, Gaithersburg, MD; first dissolved to 0.1 mg/ml isopropyl alcohol), 0.5 mM MgCl,, and 10 PM to 9 nM l*sI-NT-3 (equilibrium saturation analysis) or 200-300 PM lz51-NT-3 (all other assays) based on a dimeric molecular weight of 26,000. Slides containing adjacent brain sections were incubated in the same solutions with the addition of 300 nM unlabeled NT-3 to define nonspecific binding. Recombinant human ciliary neurotrophic factor (hCNTF, Masiakowski et al.. 1991) and BDNF (Leibrock et al., 1989) , provided by Drs. Nikos Panayotatos (Regeneron) and James' Miller (Amgen), respectively, and muNGF (Suda et al., 1978) were prepared by established methods. Various concentrations of each agent were used to compete with lz51-NT-3 binding in several experiments. As with BDNF, NT-3, and NGF, hCNTF was shown to be biologically active in the 0.2 ng/ ml ranae as determined bv the survival of 40% of E8 ciliarv ganglion neurons after 24 hr of bioassay. Following the incubation, tdesecfions were washed for 0.5 hr in the phosphate buffer. The association and dissociation of 300 PM lz51-NT-3 binding after a 1 hr wash (association experiment) or 3.5 hr incubation (dissociation experiment) was also determined. After washing, sections were fixed for 10 min in 4% paraformaldehyde at 22°C rinsed for 2 set in water at 22°C and dried within 5 min by a stream of room temperature air.
The labeled sections and l*SI-containing radioactivity standards (Amersham, Inc.) were exposed at room temperature for 2-5 d to 1251-sensitive film (Hvnerfilm. Amersham, Inc.). Additional slides contain-\ _-ing 12SI-NT-3-labeled rat'brain sections were dipped in Kodak NTB-2 photographic emulsion diluted 1: 1 with 1% glycerol. The films and slides were develooed 2-4 d (films) or l-2 weeks (slides) later in Kodak D-19 developer at' 15°C. Computer-assisted imageanalysis using a Loats RAS-CAL system was used to quantitate the amount of lz51-NT-3 bound in brain subregions using a mouse-driven cursor (Altar et al., 1984) .
Data analysis. After generation of autoradiographs, the horizontal brain sections were scraped from the slides with a razor blade, placed into 12 x 75 mm borsosilicate glass tubes, and assayed for radioactive decav using a Packard gamma counter (Cobra model). Kd values were calculated for four brams under nonequilibrium association and dissociation conditions (Weiland and Molinoff. 198 1) . Eauilibrium dissociation and association rate constants were obtained -under pseudofirst order conditions, since far less than 10% of free ligand was bound to sections after 3 hr of incubation. Kd and B,,, values were calculated by equilibrium saturation analysis with each of four brains according to the best fit to a parabola by iterative, nonlinear regression analysis (Rodbard and Lewald, 1970) . IC,, values were calculated by the method of Bliss and James (1966) . Statistical analyses for between-group comparisons were made with Dunnet's t test following a one-way analysis of variance.
Results
In preliminary studies, 40-400 PM concentrations of lZ51-NT-3 were found to bind in a dense and heterogeneous manner to horizontal and coronal sections of rat brain. Most (70-90%) of the binding was displaced by a 1 OOO-fold greater concentration of NT-3. Little or no lZ51-NT-3 binding was lost by alcoholxylene defatting procedures. Because displaceable binding was robust in the caudate-putamen, neocortex, and hippocampus, horizontal sections that contained these areas were used for subsequent quantitative studies.
Kinetic studies showed that lZSI-NT-3 associated to and dissociated from its displaceable binding to horizontal sections in a consistent manner across brain regions. The amount of binding varied by 4-20% (SEM) at association time points and by lo-25% at dissociation time points. The association of 200 PM lz51-NT-3 increased until 3 hr, at which time equilibrium was achieved and no additional binding was obtained during an additional 5 hr incubation (Fig. 1, top panel) . The association rate constant for binding to these sections was 0.0074 x lo9 min-I mole-'. A highly significant linear fit 0, < 0.001) was obtained for each association curve plotted as a function of log time by log amount bound, with F (model, error degrees of freedom) values of 48 1 (1, 49) for total bound, 136 (1, 49), nonspecific bound, and 239 (1, 49), specific bound. Sections incubated for 3.5 hr with 200 PM 1251-NT-3 were also washed in buffer containing 200 nM NT-3 from 2 min to 18 hr. This Following association experiments, sections were washed for 1 hr. After 3.5 hr of equilibrium binding, the labeled sections were placed for various times in 70 ml PBS that contained 200 nM NT-3. NSB, nonspecific binding; SB, specific binding. Table 1 . Capacity and affinity of low-and high-affinity 9-NT-3 and 9-rhNGF binding to brain The relative amounts of NT-3 binding were evaluated from visual evaluation of autoradiographs generated with 300 PM lz51-NT-3. The nonspecific binding with 300 nM NT-3 appeared uniform thorughout the brain sections and accounted for only 10-201 of the total amount of bound ligand. Abbreviations after each area refer to the labels in Figure 5 . ns, the area is not shown in Figure 5 . revealed a dissociation of specific 1251-NT-3 binding at a rate of 19.4 x 1O-4 min-' (Fig. 1, bottom panel) . The ratio of the kinetically derived dissociation and association rate constants (k-,/k,; Weiland and MolinolT, 1981) gave an average equilibrium dissociation constant (KJ value of 227 f 28 PM (Table  1) .
Additional horizontal brain sections equilibrated with 10 PM to 9 nM lz51-NT-3 revealed a saturation isotherm that was clearly biphasic and displaceable (Fig. 2, left) . Scatchard analysis (B/F vs. B) confirmed the biphasic nature of binding (Fig. 2, right) . The saturation of displaceable binding from 10-750 PM was used to calculate the fit for high-affinity I& and B,,, values by nonlinear regression analysis. The Kd was 269 + 64 PM and the capacity of binding was 26 + 3 fmol/mg protein (Table 2) . A higher range of concentrations, from 0.75 to 9 nM, revealed a second plateau of specific binding of lower affinity (Kd = 2.8 + 0.34 nM) and higher capacity (Bmax = 170 + 14 fmol/mg protein; Table 2 . NSB, nonspecific binding; SB, specific binding. Table 2 ). The B,,,,, value calculated for the entire range of 10 PM to 9 nM was an additive function of the separate B,,, values for the high-and low-affinity sites. The high-affinity component of 1Z51-labeled recombinant human NGF (lZ51-rhNGF) binding associated more quickly and dissociated more slowly than did 300 PM '251-NT-3 binding and bound with about 4-to lo-fold greater affinity and at least 3-fold lower density than did 1251-NT-3 (Table 1) .
To address the pharmacology of 1251-NT-3 binding, sections that were still wet from the final rinse were swabbed from the slides and counted after being incubated in 300 PM lZSI-NT-3 with or without various concentrations of competing molecules (Fig. 3) . '*51-NT-3 binding was not prevented by coincubation with up to 100 nM of either muNGF or hCNTF. NT-3 competed with 300 PM "151-NT-3 on an apparent mole-for-mole basis (IC,, of 420 f 60 PM) and noncooperatively for a homogeneous population of binding sites, as Hill coefficients (nH) did not significantly differ from unity (nH = 1.2 f 0.26). A replicate experiment with brains from four additional animals used image analysis to measure the inhibition of lZ51-NT-3 binding over eight concentrations of NT-3 (10 PM to 200 nM) that were more concentrated over the IC,, value of 420 PM (Fig. 4) . The amounts of lz51-NT-3 binding in several brain areas were measured directly from digitized autoradiographic films and quantitative image analysis techniques (Altar et al., 1984) . As expected, the amounts of 1251-NT-3 binding in several of these more densely labeled areas exceeded the average amount of binding to the swabbed horizontal sections (compare Figs. 3 and 4) . NT-3 inhibited lZSI-NT-3 binding with an apparent slight shoulder at approximately 0.2 nM, which was midway along the steepest portion of the curve. '251-NT-3 binding was again potently inhibited in the dentate molecular layer and superficial cortex, giving IC,, values of 200 f 18 and 544 + 10 1 PM, respectively, and Hill coefficients that, again, did not differ from unity (0.95 f 0.05 and 0.93 + 0.22, respectively). BDNF also competed for most of the binding of 300 PM lz51-NT-3 binding (IC,, = 800 + 108 PM; IZ = 4) but did so in a distinctly biphasic manner over the 50 PM to 100 nM concentration range using swabbed brain sections (Fig. 3) . The Hill coefficient for inhibition was 0.33 k 0.019, consistent with ligand inhibition to multiple sites (Wieland and Molinoff, 198 1). Inhibition by BDNF could be resolved into two separate curves by determining IC,, values from competition with 10 PM to 1 nM BDNF and from 200 PM to 100 nM BDNF. IC,, and Hill coefficient values for these two ranges of unlabeled BDNF were 230 + 100 PM (nH = 0.76 k 0.18) and 37 f 2.9 nM (nH = 0.94 f 0.05), respectively. As with the swabbed brain sections, microdensitometry of the autoradiographs showed that BDNF displaced lz51-NT-3 binding in a biphasic manner, and at about the same concentrations as in the swabbed sections (compare Figs. 3, 4) .
Autoradiographs of either coronal or horizontal rat brain sections revealed a topography of specific lz51-NT-3 binding (Fig.  5 ) that was quite distinct from that previously shown for NGF. These patterns are summarized in Table 2 , and the letter-number pairs identify the labels in Figure 5 . The highest levels of binding were found in the anterior olfactory nucleus, nucleus of the lateral olfactory tract, and the hippocampus, including the dentate gyrus, stratum oriens and radiatum, the amygdala, anterior thalmus, and the neocortex. In particular, the first and second layers of neocortex were prominently labeled in the frontal, parietal, and cingulate regions. Layers 1 and 2 were also labeled in the entorhinal cortex. Intermediate binding was also found throughout nucleus accumbens, caudate-putamen, interpeduncular nucleus, ventral and dorsal horns of the spinal cord, superior colliculus, and other areas (Table 2 ). Lower amounts of specific binding were present in the pars compacta, medial and lateral geniculate nuclei, medial septum, thalamic nuclei, hypothalamus, pars reticulata, and cerebellum. Little or no displaceable binding was found in the globus pallidus, or in other regions of the pons, medulla, or other amygdaloid nuclei. No displaceable binding was detected in myelinated fiber bundles Figure 5 . Coronal rat brain sections were incubated in 300 PM 1251-NT-3 alone or with 300 nM NT-3 to define nondisplaceable binding in adjacent sections. The numbers in each panel refer to the labels for each anatomical region listed in Table 2 . Note the high levels of binding in the molecular layer of dentate gyrus and stratum oriens and radiatum of hippocampus (Z-L), caudate-putamen (E-Z), and superficial neocortex (A-L).
including the corpus callosum, anterior commissure, internal capsule, or the interbulbar internal capsule, or in circumventricular organs such as the choroid plexus or ependymal cell layers. Specific binding was also absent from peripheral organs, including liver, muscle, kidney, pancreas, lung, stomach, intestine, and heart (data not shown).
Ten days of exposure to photographic emulsion and cresyl violet counterstaining for Nissl substance revealed intense; displaceable labeling in the almost neuron-free first layer of neocortex and the second neocortical layer (Fig. 64 , the stratum oriens, radiatum, and molecular layers of hippocampus (Fig.  6C ) and throughout the caudate-putamen (Fig. 6B) . No labeling was seen in pyramidal or granule cell layers of hippocampus (Fig. 6C) , or in the fiber bundles of the internal capsule (Fig.  6E) . 1251-NT-3 did not accumulate silver grains in cell bodies or nuclei of any brain area in the hundreds of sections analyzed. Instead, the labeling by 1251-NT-3 was reminiscent of binding to nerve terminals, in terms ofboth the diffuse pattern of labeling and its predominance in areas with dense nerve terminal innervation patterns (e.g., molecular layer of hippocampus, layer 1 of neocortex).
To address species similarities or differences in binding, sections from cat and human brains were also used. A pattern of binding in cat brain was obtained that closely resembled that observed for rat, particularly as evidenced by intense labeling of striatum, neocortex, hippocampus, and olfactory areas (Fig.  7) . Sections from the human basal ganglia (Fig. 8) revealed a similar distribution for 12SI-NT-3 binding to the caudate-putamen, neocortex, superficial and deeper neocortex, nucleus accumbens, fundus of striatum, and septum, but also in claustrum, which was not labeled in the rat. lZ51-NT-3 showed no specific labeling of myelinated fiber paths, globus pallidus, or hypothalamus, also as seen in coronal rat brain sections (Fig. 5) . No obvious differences in 1251-NT-3 binding were noted between the brains obtained from patients diagnosed with or without Alzheimer's disease.
Discussion
Receptor autoradiography with biologically active 1251-NT-3 has revealed that this neurotrophin binds with high affinity in a saturable, reversible, and pharmacologically specific manner to rat brain and with a very different distribution from that observed for Y-NGF binding. These findings, and the high affinity of BDNF for about half of lZ51-NT-3 binding, indicates that endogenous NT-3 and BDNF may have neurotrophic or other physiological effects in a variety of brain areas and provide a basis for both in vitro and in vivo studies to assess potential sites of action for these neurotrophins.
Kinetics and pharmacology of high-afinity '251-INT-3 binding
As determined by Scatchard analysis, lZSI-NT-3 specifically bound to rat brain sections with high (269 PM) and low (2.8 nM)
affinities. Thus, like the binding of BDNF (Rodriguez-T6bar et al., 1990) or NGF (Sutter et al., 1979) to sensory neurons, and lZ51-NT-3 binding to trkB-expressing fibroblasts (Squint0 et al., 199 l) , NT-3 binds to high-and low-affinity sites in brain. Because the concentration of 1251-NT-3 required to half-saturate high-affinity binding was 2-to 1 O-fold higher than that observed for i251-BDNF or 1251-NGF binding to sensory neurons, the high- Figure 6 . Emulsion autoradiography of coronal brain sections incubated with 300 PM W-NT-3 alone (A, C, E) or in the presence of 300 no unlabeled NT-3 (B, 0, F). Darkfield illumination reveals intense accumulations of silver grains in the first two layers (1,2) of cingulate cortex (A), in the stratum oriens (0) stratum radiatum (R), and molecular layers (MOL) of hippocampus (C), and throughout the caudate-putamen (E). Brightfield illumination of these cresyl violet sections revealed a low density of nondisplaceable silver grains in the molecular (LM), pyramidal (P), and granule (G) cell layers of hippocampus, in the corpus callosum, and in the fiber bundles of the internal capsule. Figure 7 . Coronal sections of an adult eat brain were incubated with 300 PM 12SI-NT-3. The binding of 300 PM lZ51-NT-3 throughout adjacent sections in the presence of 300 nM NT-3 (to define nondisplaceable binding) resembled the level of gray observed in the corpus callosum in A-l). Note the similarity of binding to rat sections in Figure 5 .
affinity nature of this binding was also evaluated with nonequilibrium analysis. The Kd value of 227 PM determined by the ratio of the dissociation and association rate constants agreed closely with the 269 PM value obtained under equilibrium conditions. In the dissociation experiments, '*%NT-3 dissociation proceeded over several hours but only in the presence of a 1 OOOfold excess concentration of NT-3. This requirement for excess homologous ligand to promote the dissociation of high-affinity neurotrophin ligand binding has also been reported for the highbut not low-affinity binding of BDNF (Rodriguez-TCbar et al., 1990) and NGF (Sutter et al., 1979; Altar et al., 1991a) , and is again consistent with the labeling by lZ51-NT-3 of a high-affinity site. Pharmacological analysis of the high-affinity binding of 300 PM 1251-NT-3 to brain sections revealed that NT-3 and BDNF, but neither NGF nor hCNTF competed for binding. Recent observations with PC12 cells and fibroblasts have shown that the trk family of proto-oncogenes represents specific and biologically relevant tyrosine kinases that can function as receptors for the neurotrophins. Specifically, t&A, trkB, and trkC bind NGF, BDNF and NT-3, respectively, with high affinity (Klein et al., 1989 (Klein et al., , 1991 Lamballe et al., 1991; Soppet et al., 1991; Squint0 et al., 1991) . NT-3 can also bind to trkA and trkB as well as trkC in these cells (Rodriquez-Tebar et al., 1990 ) and can mediate signal transduction through either receptor (Lamballe et al., 199 1; Soppet et al., 199 1; Squint0 et al., 199 1) . trkA does not appear to have been recognized in brain sections by lZ51-NT-3, since NGF did not inhibit i251-NT-3 binding to any region of horizontal brain sections. Also, the topography of 1251-NT-3 binding did not resemble that of 1251-NGF (Richardson et al., 1986; Raivich and Kruetzberg, 1987; Altar et al., 199 1 a,b) . Unlabeled NT-3 prevented lZ51-NT-3 binding at a concentration about equal to the i251-NT-3 concentration and with a Hill coefficient near unity, consistent with a noncooperative inhibition of binding from independent sites (Wieland and Molinoff, 198 1) . In contrast, BDNF inhibited NT-3 binding but did so in a clearly biphasic manner, with IC,, values of 230 PM and 37 nM. It is of considerable interest then that the pattern of trkB localization by in situ hybridization (Vasquez and Ebendal, 199 1) resembles the distribution of 1251-NT-3 binding that was most displaced by 300-400 PM BDNF in the neocortex, septum, and caudateputamen.
The residual lZ51-NT-3 binding in the presence of 1 nM BDNF is presumably to trkC sites. Although no trkC-specific antibody yet exists, in situ hybridization with an RNA probe for the extracellular domain of trkC resembles this binding in many brain regions. Thus, 12*1-NT-3 appears to bind equally well to both trkC and trkB, whereas BDNF recognizes the trkB and trkC components of 1251-NT-3 binding with high and low potency, respectively. The subtle shoulder in the curve for NT-3 inhibition of labeled NT-3 binding may reflect slightly different potencies for NT-3 competition at trkB and trkC sites. Alternatively, lZSI-NT-3 may also bind to truncated forms of trkB (Klein et al., 1989) or trkC (Lamballe et al., 199 1) 
in brain.
Significantly different affinities of BDNF but not NT-3 for these putative truncated trk proteins (Lamballe et al., 1991) or trkB and trkC receptors might explain the clearly heterogeneous displacement of '251-NT-3 by BDNF but not by NT-3. In addition, the trk family of gene products shares a high level of homology not only among themselves but also with other tyrosine kinases. were incubated with 300 PM lZSI-NT-3. Intense, highly displaceable labeling was present in the caudate nucleus (CZV), putamen (Z'), nucleus accumbens (NA), fundus of striatum CfSt), claustrum (CLAU), bilateral septum (SEPT'), amygdala (AMYG), subcallosal cortex (SC Cx), insular cortex (Z&x), frontal cortex (FCx), and first layer of cortex (I Cx). The low binding in the globus pallidus (GP), fomix (Fornix), anterior commissure (UC), internal capsule (ic), corpus callosum (cc), external or internal globus pallidus (GPe, Gpi), or lateral hypothalamus (LZZA) were not displaced by excess NT-3. LK lateral ventricle. Therefore, it is possibIe that NT-3 also recognizes other, as yet undiscovered, tyrosine kinase receptors with complex pharmacological profiles, and these may include BDNF-sensitive sites.
Distribution of NT-3 binding in mammalian brain 1x51-NT-3 bound in a regionally heterogeneous manner throughout coronal or horizontal sections. These binding patterns were conserved across species and were consistently found between experiments. In contrast, the 1 O-30% nondisplaceable component of 1251-NT-3 binding in the presence of excess NT-3 was homogeneously distributed at both the dry film and emulsion levels of resolution. The uniform topography of this nondisplaceable binding may represent receptor-independent association of 1251-NT-3 to diverse tissue components, including myelinated fiber bundles and nonspecific protein binding within brain parenchyma. A larger proportion of nondisplaceable binding has been reported for 1251-muNGF binding to tissue sections (Richardson et al., 1986; Raivich and Kreutzberg, 1987) . A decrease in nondisplaceable *251-rhNGF binding to brain and spinal cord sections (Jakeman et al., 1990; Altar et al., 199 la,b) has been obtained with the protein carriers used by the present methods, and these conditions probably contributed to the high specificity of the NT-3 signal obtained here. Nevertheless, slightly more (70-90%) *251-NT-3 binding was displaced by excess homologous ligand than is lz51-rhNGF (6040%; Altar et al., 199 la, b) under identical binding assay conditions.
The amount of high-affinity lz51-NT-3 binding in swabbed brain sections exceeded by at least threefold the amount reported even within areas with the densest NGF binding (Altar et al., 199 la, b) . Using microdensitometry, 1251-NT-3 binding was yet again three-to fourfold greater in hippocampus and superficial neocortex than the average amount of 1251-NT-3 binding in swabbed horizontal sections. Thus, 1251-NT-3 binding exceeds by about lo-fold the amount of lZSI-NGF binding when areas with the greatest densities are compared. The topography of 1251-NT-3 binding to rat brain sections also clearly differed from 1251-NGF binding (Richardson et al., 1986; Raivich and Kreutzberg, 1987; Altar et al., 199 la,b) . None of the cholinergic nuclei in the diagonal band, nucleus basalis, or seventh cranial nerve nucleus were labeled by '**I-NT-3, whereas these areas show the greatest amounts of high-affinity labeling with lz51-NGF (Richardson et al., 1986; Raivich and Kreutzberg, 1987; Altar et al., 1990a,b) . Unlike lZSI-NGF (Richardson et al., 1986; Raivich Binding and Kreutzberg, 1987) , emulsion autoradiography with 1251-NT-3 failed to find neuronal cell body binding in any brain region in sections at 25 coronal levels. Instead, lZSI-NT-3 binding appeared to predominate in brain regions that are replete with nerve terminals. For example, the neuron-free first layer of neocortex and layer 2 bound IzSI-NT-3, and more so in rostra1 cortex. The absence of labeling on neuronal somata, and the diffuse pattern of labeling in most brain regions suggest that terminal rather than cell body labeling is a distinct property of high-affinity iz51-NT-3 binding. This property of rZ51-NT-3 binding may also explain the relatively low binding of iZSI-NT-3 in the molecular layer of cerebellum. The granule cell layer is labeled with trkC mRNA using in situ hybridization techniques (Lamballe et al., 199 1) . A relatively diminished translation of trkC message into functional receptor in cerebellum may explain the presence of trkC mRNA but not lZ51-NT-3 binding in the cerebellar granule layer, and the presence of functional NT-3 receptors may result from the transport of this binding site to terminals within the molecular layer. Clearly, selective denervation techniques are required to identify neuronal terminals upon which these 1251-NT-3 binding sites may reside.
The present results allow some comparisons to be made between the patterns of lZ51-NT-3 binding and LNGFR immunostaining in several rat and human brain areas. This comparison is of interest in part because LNGFR recognizes many rat brain regions that are not labeled by high-affinity lZ51-NGF binding (Pioro and Cuello, 1988,199O; Batchelor et al., 1989; CohenCorey et al., 1989; Gibbs et al., 1989; Koh et al., 1989; Woolf et al., 1989; Yan and Johnson, 1989; Cue110 et al., 1990) . Some of these areas include hippocampus, neocortex, raphe nuclei, and olfactory bulb. Unlike NGF, lz51-NT-3 binding is present in these areas of rat brain, and thus may result from an interaction with LNGFR. Of these areas, the hippocampus, neocortex, and olfactory pathways also express high levels of NT-3 and trkC mRNA (Emfors et al., 1990; Lamballe et al., 1991) . 125I-NT-3 binding was also clearly evident in cat and human brain and resembled that seen in rat brain sections, including binding to septum, amygdala, caudate-putaman, nucleus accumbens, and superficial neocortex. LNGFR immunostaining has been found in the medial septum, diagonal band, nucleus basalis, and cerebellar Purkinje cell of adult human and monkey (Hefti et al., 1986; Kordower et al., 1988; Hefti and Mash, 1989; Mufson et al., 199 1) and in primate hippocampus, dentate gyrus, olfactory tubercle, and layers 1,2, and 4 of neocortex (Kordower et al., 1988; Mufson et al., 1991) . Thus, as in rat, some of the high-affinity lz51-NT-3 binding is found in primate species in brain regions that also contain the LNGFR. However, 1251-NT-3 binding also appears in a number of rodent or primate brain regions in which LNGFR is either absent or barely detectable, including claustrum, nucleus accumbens, fundus of striatum, neostriatum, superficial neocortex, substantia nigra, dorsal raphe nucleus, central gray, and basolateral amygdala. It thus appears unlikely that LNGFR is required in these areas for highaffinity NT-3 or BDNF binding, since either ligand potently displaced 1251-NT-3 in each brain area where LNGFR is not detected. This conclusion is consistent with observations of LNGFR-independent binding of NGF or BDNF for trkA (Klein et al., 199 1) or trkB-transfected cells, respectively (Glass et al., 1991; Klein et al., 1991; Soppet et al., 1991; Squint0 et al., 1991) .
The high-affinity component of 1251-NGF binding of prior studies reflects the predominant if not exclusive physiological effects of NGF on a subset of brain cholinergic neurons. In a similar manner, the demonstration of high-affinity 1251-NT-3 binding in rat, cat, and human brain supports a role for this neurotrophin in adult brain function, and provides an anatomical basis for investigations of brain functions for BDNF as well as NT-3. In vitro bioassays have revealed that BDNF and NT-3 can each promote the survival and phenotypic expression of dopaminergic, GABAergic, and choline& neurons derived from embryonic rat brain (Alderson et al., 1990; Kniisel et al., 1990; Hyman et al., 199 la,b) . More recent in vivo studies have shown that BDNF enhances the survival of septohippocampal cholinergic neurons following axotomy (Morse et al., 1992) , elevates dopamine turnover in the caudate-putamen, and augments behavioral functions of nigrostriatal neurons . These functional studies, and the localization of high-affinity lZSI-NT-3 binding in brain, indicate that BDNF and NT-3 are likely to have more widespread effects than NGF on the developing, adult, or aging brain, or following neuronal injury and subsequent repair.
